Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Ajinomoto becomes first partner for Albireo's lead drug elobixibat

This article was originally published in Scrip

Executive Summary

Albireo has struck the first alliance for its lead development project, the bowel disorder drug elobixibat (A3309), with Ajinomoto Pharmaceuticals for a number of Asian markets including Japan.

You may also be interested in...



Albireo Making Headway In Rare Pediatric Liver Diseases With IBAT Inhibition

Biotech hopes to launch a Phase III trial in the rare disorder PFIC before year’s end. It thinks its therapy could offer similar benefits to surgery in reducing pruritus and improving liver parameters.

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: US tax policies challenge pharma; J&J’s long-time R&D head to retire; Legend Biotech’s CEO talks about plans; BMS disappointment in ulcerative colitis; and another gene therapy partnership for Takeda.

Coronavirus Update: Brii Files US EUA For Antibody Combo

Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral. 

Topics

Related Companies

UsernamePublicRestriction

Register

SC016888

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel